162 related articles for article (PubMed ID: 37073741)
1. Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.
Thompson PA; Malogolowkin MH; Furman WL; Piao J; Krailo MD; Chung N; Brock L; Towbin AJ; McCarville EB; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Tiao GM; Weldon CB; O'Neill AF; Rodriguez-Galindo C; Meyers RL; Katzenstein HM
Pediatr Blood Cancer; 2023 Jul; 70(7):e30365. PubMed ID: 37073741
[TBL] [Abstract][Full Text] [Related]
2. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
O'Neill AF; Towbin AJ; Krailo MD; Xia C; Gao Y; McCarville MB; Meyers RL; McGahren ED; Tiao GM; Dunn SP; Langham MR; Weldon CB; Finegold MJ; Ranganathan S; Furman WL; Malogolowkin M; Rodriguez-Galindo C; Katzenstein HM
J Clin Oncol; 2017 Oct; 35(30):3465-3473. PubMed ID: 28892430
[TBL] [Abstract][Full Text] [Related]
4. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of irinotecan combined with first-line chemotherapeutics against pediatric hepatoblastoma with pulmonary metastasis.
Hu H; Zhang W; Li J; Li F; Wen Y; Mei Y; Huang D
Pak J Pharm Sci; 2022 Sep; 35(5):1301-1306. PubMed ID: 36451557
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
Srinivasan S; Prasad M; Parambil BC; Shrimal A; Gollamudi VRM; Subramani V; Ramadwar M; Khanna N; Baheti AD; Gala K; Patil V; Laskar S; Qureshi S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Jul; 70(7):e30302. PubMed ID: 37046413
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of 100 patients with hepatoblastoma based on a new risk stratification].
Zhen ZZ; Liu JC; Zhou L; Xu Z; Zhang ZC; Sun FF; Lu SY; Zhu J; Wang J; Huang JT; Sun XF
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):228-232. PubMed ID: 33601490
[No Abstract] [Full Text] [Related]
8. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
9. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.
Daw NC; Chi YY; Kalapurakal JA; Kim Y; Hoffer FA; Geller JI; Perlman EJ; Ehrlich PF; Mullen EA; Warwick AB; Grundy PE; Paulino AC; Gratias E; Ward D; Anderson JR; Khanna G; Tornwall B; Fernandez CV; Dome JS;
J Clin Oncol; 2020 May; 38(14):1558-1568. PubMed ID: 32134700
[TBL] [Abstract][Full Text] [Related]
10. Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival.
Powers JM; Pacheco MM; Wickiser JE
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e171-e173. PubMed ID: 29668545
[TBL] [Abstract][Full Text] [Related]
11. Current chemotherapeutic approaches for hepatoblastoma.
Watanabe K
Int J Clin Oncol; 2013 Dec; 18(6):955-61. PubMed ID: 24052132
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong.
Liu APY; Ip JJK; Leung AWK; Luk CW; Li CH; Ho KKH; Lo R; Chan EKW; Chan ACY; Chung PHY; Chiang AKS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27482. PubMed ID: 30270490
[TBL] [Abstract][Full Text] [Related]
13. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
14. Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience.
Zhang YT; Feng LH; Zhong XD; Wang LZ; Chang J
Pediatr Hematol Oncol; 2015 Feb; 32(1):18-25. PubMed ID: 24852330
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
Katzenstein HM; Malogolowkin MH; Krailo MD; Piao J; Towbin AJ; McCarville MB; Tiao GM; Dunn SP; Langham MR; McGahren ED; Finegold MJ; Ranganathan S; Weldon CB; Thompson PA; Trobaugh-Lotrario AD; O'Neill AF; Furman WL; Chung N; Randazzo J; Rodriguez-Galindo C; Meyers RL
Cancer; 2022 Mar; 128(5):1057-1065. PubMed ID: 34762296
[TBL] [Abstract][Full Text] [Related]
16. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group.
Van Tornout JM; Buckley JD; Quinn JJ; Feusner JH; Krailo MD; King DR; Hammond GD; Ortega JA
J Clin Oncol; 1997 Mar; 15(3):1190-7. PubMed ID: 9060563
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731.
Vasudevan SA; Meyers RL; Finegold MJ; López-Terrada D; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Tiao GM; Weldon CB; Malogolowkin MH; Krailo MD; Piao J; Randazzo J; Towbin AJ; BethMcCarville M; O'Neill AF; Furman WL; Rodriguez-Galindo C; Katzenstein HM
J Pediatr Surg; 2022 Oct; 57(10):251-256. PubMed ID: 35810020
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
19. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
[TBL] [Abstract][Full Text] [Related]
20. Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy.
Nguyen R; McCarville MB; Sykes A; Mao S; Wu J; Langham MR; Furman WL
Int J Clin Oncol; 2018 Oct; 23(5):900-907. PubMed ID: 29744604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
